0001437749-14-011906.txt : 20140627
0001437749-14-011906.hdr.sgml : 20140627
20140626160739
ACCESSION NUMBER: 0001437749-14-011906
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140624
FILED AS OF DATE: 20140626
DATE AS OF CHANGE: 20140626
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Furiex Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001484478
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 271197863
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3900 PARAMOUNT PARKWAY
STREET 2: SUITE 150
CITY: MORRISVILLE
STATE: NC
ZIP: 27560
BUSINESS PHONE: 919-456-7800
MAIL ADDRESS:
STREET 1: 3900 PARAMOUNT PARKWAY
STREET 2: SUITE 150
CITY: MORRISVILLE
STATE: NC
ZIP: 27560
FORMER COMPANY:
FORMER CONFORMED NAME: PPD Therapeutics, Inc.
DATE OF NAME CHANGE: 20100218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: COVINGTON PAUL S
CENTRAL INDEX KEY: 0001181153
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34641
FILM NUMBER: 14942809
MAIL ADDRESS:
STREET 1: 3116 BRAEMAR DRIVE
CITY: WILMINGTON
STATE: NC
ZIP: 28401
4
1
rdgdoc.xml
FORM 4
X0306
4
2014-06-24
0001484478
Furiex Pharmaceuticals, Inc.
FURX
0001181153
COVINGTON PAUL S
C/O FURIEX PHARMACEUTICALS, INC.,
3900 PARAMOUNT PARKWAY, SUITE 150
MORRISVILLE
NC
27560
1
Senior VP-Clinical Operations
Common Stock
2014-06-24
4
M
0
10368
17.80
A
32891
D
Common Stock
2014-06-24
4
S
0
10368
104.12
D
22523
D
Stock Options (to buy)
17.80
2014-06-24
4
M
0
10368
0
D
2022-02-24
Common Stock
10368
0
D
Stock Options (to buy)
15.0000
2021-05-09
Common Stock
26000
26000
D
Stock Options (to buy)
13.1600
2021-10-03
Common Stock
37944
37944
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.01 to $104.28, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
All options became 100% vested on June 11, 2014 in connection with the Agreement and Plan of Merger dated as of April 27, 2014 by and among Forest Laboratories, Inc., Royal Empress, Inc. and Furiex Pharmaceuticals, Inc.
/s/ Paul S. Covington
2014-06-26